Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies

Nature Reviews Clinical Oncology

Volumn 12, Issue 2, 2015, Pages 73-74

  Hubbard, Joleen M ^a   Grothey, Axel ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; REGORAFENIB; TAS 102; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; DIARRHEA; DISEASE COURSE; DNA REPLICATION; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; ONCOGENE N RAS; ONCOGENE RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SALVAGE THERAPY; SHORT SURVEY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 84923202077     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.233     Document Type: Short Survey

References (10)

1. Heinemann, V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065-1075 (2014).
2. Stintzing, S. et al. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population [abstract LBA11]. Ann. Oncol. 25 (Suppl. 5), v1-v41 (2014).
3. Venook, A. P. et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (mCRC) [abstract]. J. Clin. Oncol. 32 (5s Suppl.), LBA3 (2014).
4. Lenz, H. et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC) [abstract]. Ann. Oncol. 25 (Suppl. 4), A5010 (2014).
5. Arnold, D. et al. Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of F P, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): a phase III non-inferiority trial (AIO KRK 0207) [abstract]. J. Clin. Oncol. 32 (5s Suppl.), 3503 (2014).
6. Chibaudel, B. et al. Bevacizumab-erlotinib as maintenance therapy in metastatic colorectal cancer. Final results of the GERCOR DREAM study [abstract 4970]. Ann. Oncol. 25 (Suppl. 4), iv167-iv209 (2014).
7. Koopman, M. et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC) [abstract]. J. Clin. Oncol. 32 (Suppl. 3), LBA388 (2014).
8. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303-312 (2013).
9. Kim, T. W. et al. CONCUR: a randomized, placebo-controlled phase 3 study of regorafenib (REG) monotherapy in Asian patients with previously treated metastatic colorectal cancer (mCRC) [abstract 500O]. Ann. Oncol. 25 (Suppl. 4), iv168-iv169 (2014).
10. Van Cutsem, E. et al. Phase III RECOURSE trial of TAS-102 vs. placebo, with best supportive care (BSC), in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies [abstract LBA13]. Ann. Oncol. 25 (Suppl. 5), v1-v41 (2014).